Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

XALience: A phase 3, open-label, multicenter, randomized study of xaluritamig plus abiraterone vs investigator’s choice in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.

Tanya B. Dorff, Leonard Joseph Appleman, Chia-Chi Lin et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps5144

TPS5144 Background: In the first-in-human (FIH) study, xaluritamig, a T-cell engager directed at six-transmembrane epithel...

Safety and efficacy of relacorilant and nab-paclitaxel in platinum resistant ovarian cancer: A GRADE assessed systematic review and meta-analysis of randomized controlled trials.

Muhammad Usama Zafar Mirza, Zain ul Abedin, Zoha Khan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17604

e17604 Background: Relacorilant, a first-in-class selective glucocorticoid receptor antagonist, is being used along with N...

Results from OCEAN II: A phase II study of encorafenib + binimetinib combination in Chinese patients with <i> BRAF <sup>V600E</sup> </i> mutated metastatic non-small cell lung cancer.

Huaqiang Zhou, Qing Zhou, Qisen Guo et al. Jun 01, 2026 pp. 8640-8640 10.1200/jco.2026.44.16_suppl.8640

8640 Background: Lung cancer is the most common cause of cancer and cancer death in China. Patients (pts) with...

Modular CAR T cells: Advancing flexibility, safety, and efficacy in solid cancer therapy.

Archana Thakur, Amy Schienschang, Molly G. Owens et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14521

e14521 Background: Chimeric antigen receptor (CAR) T cell immunotherapy has revolutionized treatment for hematological mal...

Fitbit-derived activity and heart-rate patterns for predicting 12-month hospitalization in an NIH All of Us cancer cohort.

Kenan Najjar, Wahab Ahsan, Maaz S. Imam et al. Jun 01, 2026 pp. 1629-1629 10.1200/jco.2026.44.16_suppl.1629

1629 Background: Hospitalizations in oncology are common and diverse, and are often limited in their predictive accuracy w...

AI-driven virtual transcriptome screening to identify repurposable combination partners for JIN-A02 in NSCLC.

Sangyeol Kim, Anna Jo, Ethan Seah et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20528

e20528 Background: Combination therapy is a key strategy to overcome drug resistance and improve therapeutic efficacy in n...

A phase 1b study of SYS6002 in advanced solid tumors.

Yao Zhu, Dingwei Ye, Jian Zhang et al. Jun 01, 2026 pp. 4579-4579 10.1200/jco.2026.44.16_suppl.4579

4579 Background: SYS6002 is a next-generation Nectin-4-targeting antibody-drug conjugate (ADC) utilizing a novel site-spec...

Treatment holiday for patients with metastatic hormone sensitive prostate cancer: Real-world experience at a single center.

David James VanderWeele, Maha H. A. Hussain, Masha Kocherginsky et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17105

e17105 Background: Continuous androgen deprivation therapy (ADT) is the standard for patients with hormone sensitive prost...

Systematic safety information gaps in AI-generated melanoma therapy information: An exploratory multi-platform evaluation.

Jennifer M. Hinkel, Shivani Modi, Cory Kidd Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13704

e13704 Background: Patients and clinicians increasingly use large language models (LLMs) for pharmaceutical information. P...

FAPI-CUP: A prospective cohort study of patients with cancer of unknown primary (CUP) to evaluate a novel radiotracer, fibroblast activated protein (FAPI), targeting cancer-associated fibroblasts for primary site detection.

Tharani Sivakumaran, Timothy J. Akhurst, Grace Kong et al. Jun 01, 2026 pp. 3072-3072 10.1200/jco.2026.44.16_suppl.3072

3072 Background: Cancer of unknown primary (CUP) represents a heterogeneous group of metastatic tumours for which standard...

Surufatinib for advanced or metastatic chemotherapy-refractory thymic epithelial tumor: A single-arm, single-center, phase II study.

Bei Xu, Qing Liu, Xi Guo et al. Jun 01, 2026 pp. 8119-8119 10.1200/jco.2026.44.16_suppl.8119

8119 Background: Thymic epithelial tumors (TETs), though relatively rare, represent the most common anterior mediastinal m...

Empowering pathologists as cancer precision medicine leaders: The Florida Society of Pathologists (FSP) Precision Medicine Academy (PMA) initiative.

Marilyn M. Bui, Dahul Qin, Theresa A. Boyle et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21013

e21013 Background: As cancer care increasingly relies on molecular and genomic biomarkers, pathologists play a central rol...

Efficacy and safety of vebreltinib in advanced clear cell sarcoma (VEBrant): A multicenter, phase II study.

Binghao Li, Yaling Jiang, Xin Huang et al. Jun 01, 2026 pp. 11503-11503 10.1200/jco.2026.44.16_suppl.11503

11503 Background: Clear cell sarcoma (CCS) is an ultra rare cancer with no established standard systemic therapy of proven...

DZD6008, a fourth-generation EGFR TKI, in pretreated NSCLC patients with <i>EGFR</i> C797X mutations: Results from phase 1/2 studies.

Mengzhao Wang, Elaine Shum, Ying Hu et al. Jun 01, 2026 pp. 8520-8520 10.1200/jco.2026.44.16_suppl.8520

8520 Background: Patients with EGFR-mutant NSCLC whose disease progresses on or after 3 rd...

Circulating tumor DNA (ctDNA) dynamics as early biomarkers of response to enfortumab vedotin plus pembrolizumab (EVP) in advanced urothelial carcinoma (aUC).

Mohammad Jad Moussa, Emanuele Crupi, Zachariah Thomas et al. Jun 01, 2026 pp. 4582-4582 10.1200/jco.2026.44.16_suppl.4582

4582 Background: Radiographic assessment of treatment response remains challenging in aUC. ctDNA testing offers a sensitiv...

Larynx preservation via chemotherapy-free neoadjuvant sintilimab-cetuximab-SBRT and response-adapted treatment in locally advanced laryngeal cancer: A phase II, single-arm clinical trial (the NeoVOICE study).

Shida Yan, Xing Zhang, Ya-Ni Zhang et al. Jun 01, 2026 pp. 6095-6095 10.1200/jco.2026.44.16_suppl.6095

6095 Background: The current standard of care for locally advanced laryngeal squamous cell carcinoma (LA-LSCC), including...

Patterns of use and adherence to breast cancer clinical practice guidelines among Brazilian medical oncologists: The GUIDE-Breast survey (LACOG 0924-GBECAM|D9673N00006).

Giuliano Santos Borges, Tomas Reinert, Gisah Guilgen et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23146

e23146 Background: Clinical practice guidelines are central to standardize breast cancer (BC) care and reduce disparities...

Survival, fertility preservation, and pregnancy after treatment in young patients with BRCA-associated triple-negative breast cancer.

Akemi Kataoka, Meiko Nishimura, Ayumi Kanazawa et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23345

e23345 Background: As survival outcomes improve with novel systemic therapies, fertility preservation (FP) and post-treatm...

A phase Ib/III randomized double-blinded placebo-controlled study of suvemcitug combined with trifluridine/tipiracil for refractory metastatic colorectal cancer.

Ying Yuan, Yanhong Gu, Shuqin Ni et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps3674

TPS3674 Background: Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide. For patients with metast...

A real-world study of triple-negative breast cancer patients with brain metastases: A multicenter retrospective analysis.

Meiling Wang, Weihong Zhao Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13130

e13130 Background: Triple-negative breast cancer patients with brain metastasis (TNBC-BM) have extremely poor prognosis, p...

Clinical implications of primary and metastatic tumor-informed clonal tracking for MRD assessment in oligometastatic colorectal cancer.

Hyun Jin Bang, Yongjun Cha, Hyeon-Jong Kim et al. Jun 01, 2026 pp. 3601-3601 10.1200/jco.2026.44.16_suppl.3601

3601 Background: While minimal residual disease (MRD) assays informed by primary tumor sequencing have demonstrated progno...

Associations between neighborhood disadvantage, cannabis use, and patient-reported outcomes among patients with cancer.

Brittney Greene, Shilpa Ghosh, Craig Colder et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13501

e13501 Background: Cannabis use is proliferating among oncological populations. However, research is limited on whether ca...

Improving hematology/oncology education for physician trainees through an interactive online platform.

Lyndsey Reich, Samyukta Swaminath, Kevin B. Knopf Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21008

e21008 Background: Internal Medicine residency education in Hematology/Oncology remains challenging due to the complexity...

Inpatient mortality across gastrointestinal malignancies by hospital structural characteristics in the United States, 2018–2022.

Qasim Shawesh, Emaan Tiwana, Emi Hearn et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16353

e16353 Background: Inpatient mortality among gastrointestinal (GI) cancer hospitalizations is often attributed to tumor bi...

The efficacy of adjuvant chemoendocrine versus endocrine therapy alone in hormone receptor-positive, HER2-negative early breast cancer: A meta-analysis of reconstructed individual patient data.

Khadija Mohib, Maaz Ahmad, Hira Shehzad et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12504

e12504 Background: The benefit of adding adjuvant chemotherapy to endocrine therapy for hormone receptor–positive (HR+), H...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page